Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference29 articles.
1. Significant survival improvement of patients with recurrent breast cancer in the periods 2001–2008 vs. 1992–2000;Hideo Shigematsu;BMC Cancer,2011
2. Quantitative exploration of possible reasons for the recent improvement in breast cancer survival;Berube;Breast Cancer Res Treat,2007
3. Survival improvement in Korean breast cancer patients due to increases in early-stage cancers and hormone receptor positive/HER2 negative subtypes: a nationwide registry-based study;You;J Breast Cancer,2015
4. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update;Burstein;J Clin Oncol,2014
5. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;The Lancet,2013
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta‐analysis;Cancer;2024-09-05
2. Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis;Cancer Reports;2023-03-14
3. Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study;Frontiers in Oncology;2021-06-03
4. Hormone Therapy Effects on the Uterus;Advances in Experimental Medicine and Biology;2020
5. Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan;Tzu Chi Medical Journal;2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3